


<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 19059	
In Re Application Of: Jose Repolles Moliner, et al.					
Application No. 10/544,237	Filing Date August 2, 2005	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. Unassigned
<p>Title: <b>DISULFIDE, SULFIDE, SULFOXIDE, AND SULFONE DERIVATIVES OF CYCLIC SUGARS AND USES THEREOF</b></p>					
<p>Address to:  <b>Commissioner for Patents</b>  <b>P.O. Box 1450</b>  <b>Alexandria, VA 22313-1450</b></p>					
<b>37 CFR 1.97(b)</b>					
<p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p>					
<b>37 CFR 1.97(c)</b>					
<p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="margin-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin-left: 100px;"><b>OR</b></p> <p style="margin-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>					

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
19059

In Re Application of: Jose Repolles Moliner, et al.



Application No. 10/544,237	Filing Date August 2, 2005	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. Unassigned
-------------------------------	-------------------------------	------------------------	-----------------------	------------------------------	--------------------------------

Title:

**DISULFIDE, SULFIDE, SULFOXIDE, AND SULFONE DERIVATIVES OF CYCLIC SUGARS AND USES THEREOF**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))


- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_) on \_\_\_\_\_ (Date) \_\_\_\_\_ Signature \_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on September 27, 2005 (Date)  Signature of Person Mailing Correspondence  
Frank S. DiGiglio  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: September 27, 2005

Frank S. DiGiglio  
Registration No. 31,346  
Scully, Scott, Murphy & Presser  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
516-742-4343

CC:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Jose Repolles Moliner, et al.

**Examiner:** Unassigned

**Serial No:** 10/544,237

**Art Unit:** Unassigned

**Filed:** August 2, 2005

**Docket:** 19059

**For:** DISULFIDE, SULFIDE, SULFOXIDE,  
AND SULFONE DERIVATIVES OF  
CYCLIC SUGARS AND USES THEREOF

**Dated:** September 27, 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. French Patent Publication No. 2 134 698, published December 8, 1972;
2. Shore B. et al., "Rabbits as a Model for the Study of Hyperlipoproteinemia and Atherosclerosis", *Day CE (ed) Atherosclerosis Drug Discovery* 123-141 (1976);
3. De Lucchi O., "Chemoselective Reduction of Isosorbide-2,5-Dinitrate", *Gazzetta Chimica Italiana, Societa Chimica*, 117(3):173-176 (1987), XP-000984806;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 27, 2005

  
Frank S. DiGiglio

4. European Patent Publication No. 0 290 885, published November 17, 1988;
5. Kurz K.D. et al., "Rat Model of Arterial Thrombosis Induced by Ferric Chloride", *Thrombosis Research*, 60(4):269-280 (1990);
6. Stephan Z.F. et al., "Rapid Fluorometric Assay of LDL Receptor Activity by Dil-Labeled LDL", *Journal of Lipid Research*, 34:325-330 (1993);
7. European Patent Publication No. 0 530 887 A1, published March 10, 1993;
8. Salas E. et al., "Endothelium-Independent Relaxation by 17- $\alpha$ -Estradiol of Pig Coronary Arteries", *European Journal of Pharmacology*, 258:47-55 (1994);
9. Trongvanichnam K. et al., "Effects of Chronic Oral Administration of Isosorbide Dinitrate on In Vitro Contractility of Rat Arterial Smooth Muscle", *Jpn. J. Pharmacol.*, 71:167-173 (1996);
10. Caveda L. et al., "Inhibition of Cultured Cell Growth by Vascular Endothelial Cadherin (Cadherin-5/VE-Cadherin)", *J. Clin. Invest.*, 98(4):886-893 (1996);
11. Del Maschio A. et al., "Polymorphonuclear Leukocyte Adhesion Triggers the Disorganization of Endothelial Cell-to-Cell Adherens Junctions", *The Journal of Cell Biology*, 135(2):497-510 (1996);
12. Furchgott R., "Bioassays with Isolated Vascular Tissue for Endothelium-Derived Relaxing Factor, Nitric Oxide and Nitric Oxide Donors", *Feelisch & Stamler, eds., John Wiley & Sons*, pp. 567-581 (1996);
13. Nallet J.P. et al., "Synthesis of a Series of Hexitol and Aminodeoxyhexitol Mononitrate Derivatives Containing a Sulfur Group and Pharmacological Evaluation on Isolated Rat Aortas", *Eur. J. Org. Chem.*, 933-943 (1998);
14. Hirata Y. et al., "Effect of JTV-506, a Novel Vasodilator, on Experimental Angina Model in Rats", *Journal of Cardiovascular Pharmacology*, 31(2):322-326 (1998);
15. Spranger T. et al., "How Different Constituents of Human Plasma and Low Density Lipoprotein Determine Plasma Oxidizability by Copper", *Chemistry and Physics of Lipids*, 91:39-52 (1998);
16. Feuerstein G.Z. et al., "Antithrombotic Efficacy of a Novel Murine Antihuman Factor IX Antibody in Rats", *Arterioscler Thromb Vasc Biol.*, 19:2554-2562 (1999);
17. Bombeli T. et al., "Endothelial Cells Undergoing Apoptosis Become Proadhesive for Nonactivated Platelets", *Blood*, 93(11):3831-3838 (1999);

18. Martín-Satué M. et al., "Overexpression of  $\alpha(1,3)$ -Fucosyltransferase VII is Sufficient for the Acquisition of Lung Colonization Phenotype in Human Lung Adenocarcinoma HAL-24Luc Cells", *British Journal of Cancer*, 80(8):1169-1174 (1999);
19. PCT International Publication No. WO 00/20420, published April 13, 2000;
20. Lynch S.M. et al., "Plasma Thiols Inhibit Hemin-Dependent Oxidation of Human Low-Density Lipoprotein", *Biochimica et Biophysica Acta*, 1485:11-22 (2000);
21. Pedreño J. et al., "Molecular Requirements in the Recognition of Low-Density Lipoproteins (LDL) by Specific Platelet Membrane Receptors", *Thrombosis Research*, 99:51-60 (2000);
22. Colomé C. et al., "Small Oxidative Changes in Atherogenic LDL Concentrations Irreversibly Regulate Adhesiveness of Human Endothelial Cells: Effect of the Lazaroid U74500A", *Atherosclerosis*, 149:295-302 (2000); and
23. Pedreño J. et al., "Low-Density Lipoprotein (LDL) Binds to a G-Protein Coupled Receptor in Human Platelets, Evidence that the Proaggregatory Effect Induced by LDL is Modulated by Down-Regulation of Binding Sites and Desensitization of its Mediated Signaling", *Atherosclerosis*, 155:99-112 (2001).

Reference nos. 1, 3, 4, 7, 13 and 19 were cited in a Search Report dated February 3, 2005 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of above-identified reference nos. 1, 3, 4, 7 and 13 has been described in the Search Report. The relevance of above-identified reference nos. 2, 5, 6, 8-12, 14-23 has been described in the specification.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.


Respectfully submitted,


A handwritten signature in black ink, appearing to read "F. DiGiglio".

Frank S. DiGiglio  
Registration No.: 31,346

Scully, Scott, Murphy & Presser  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343

FSD:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE  <div style="text-align: center;"> <b>LIST OF PRIOR ART CITED BY APPLICANT</b>   <i>(Use several sheets if necessary)</i> </div> <div style="text-align: center;">  </div>		<b>Atty. Docket No. (Optional)</b>  19059	<b>Application Number</b>  10/544,237				
		<b>Applicant(s)</b> Jose Repolles Moliner, et al.					
		<b>Filing Date</b> August 2, 2005	<b>Group Art Unit</b> Unassigned				
<b>FOREIGN PATENT DOCUMENTS</b>							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
		Caveda L. et al., "Inhibition of Cultured Cell Growth by Vascular Endothelial Cadherin (Cadherin-5/VE-Cadherin)", <i>J. Clin. Invest.</i> , 98(4):886-893 (1996)					
		Del Maschio A. et al., "Polymorphonuclear Leukocyte Adhesion Triggers the Disorganization of Endothelial Cell-to-Cell Adherens Junctions", <i>The Journal of Cell Biology</i> , 135(2):497-510 (1996)					
		Furchgott R., "Bioassays with Isolated Vascular Tissue for Endothelium-Derived Relaxing Factor, Nitric Oxide and Nitric Oxide Donors", <i>Feelisch &amp; Stamler, eds., John Wiley &amp; Sons</i> , pp. 567-581 (1996)					
		Nallet J.P. et al., "Synthesis of a Series of Hexitol and Aminodeoxyhexitol Mononitrate Derivatives Containing a Sulfur Group and Pharmacological Evaluation on Isolated Rat Aortas", <i>Eur. J. Org. Chem.</i> , 933-943 (1998)					
		Hirata Y. et al., "Effect of JTV-506, a Novel Vasodilator, on Experimental Angina Model in Rats", <i>Journal of Cardiovascular Pharmacology</i> , 31(2):322-326 (1998)					
		Spranger T. et al., "How Different Constituents of Human Plasma and Low Density Lipoprotein Determine Plasma Oxidizability by Copper", <i>Chemistry and Physics of Lipids</i> , 91:39-52 (1998)					
		Feuerstein G.Z. et al., "Antithrombotic Efficacy of a Novel Murine Antihuman Factor IX Antibody in Rats", <i>Arterioscler Thromb Vasc Biol.</i> , 19:2554-2562 (1999)					
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>					
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE  <div style="text-align: center;"> <b>LIST OF PRIOR ART CITED BY APPLICANT</b>   <i>(Use several sheets if necessary)</i> </div> <div style="text-align: center;">  </div>		<b>Atty. Docket No. (Optional)</b>  19059	<b>Application Number</b>  10/544,237					
		<b>Applicant(s)</b> Jose Repolles Moliner, et al.						
		<b>Filing Date</b> August 2, 2005	<b>Group Art Unit</b> Unassigned					
<b>FOREIGN PATENT DOCUMENTS</b>								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		2 134 698	12/8/72	France				
		0 290 885	11/17/88	EPO				
		0 530 887 A1	3/10/93	EPO				
		WO 00/20420	4/13/00	PCT				
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>								
		Shore B. et al., "Rabbits as a Model for the Study of Hyperlipoproteinemia and Atherosclerosis", <i>Day CE (ed) Atherosclerosis Drug Discovery</i> 123-141 (1976)						
		De Lucchi O., "Chemoselective Reduction of Isosorbide-2,5-Dinitrate", <i>Gazzetta Chimica Italiana, Societa Chimica</i> , 117(3):173-176 (1987), XP-000984806						
		Kurz K.D. et al., "Rat Model of Arterial Thrombosis Induced by Ferric Chloride", <i>Thrombosis Research</i> , 60(4):269-280 (1990)						
		Stephan Z.F. et al., "Rapid Fluorometric Assay of LDL Receptor Activity by Dil-Labeled LDL", <i>Journal of Lipid Research</i> , 34:325-330 (1993)						
		Salas E. et al., "Endothelium-Independent Relaxation by 17- $\alpha$ -Estradiol of Pig Coronary Arteries", <i>European Journal of Pharmacology</i> , 258:47-55 (1994)						
		Trongvanichnam K. et al., "Effects of Chronic Oral Administration of Isosorbide Dinitrate on In Vitro Contractility of Rat Arterial Smooth Muscle", <i>Jpn. J. Pharmacol.</i> , 71:167-173 (1996)						
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>				
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE		<b>Atty. Docket No. (Optional)</b> 19059		<b>Application Number</b> 10/544,237			
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant(s)</b> Jose Repolles Moliner, et al.					
		<b>Filing Date</b> August 2, 2005		<b>Group Art Unit</b> Unassigned			
		<b>FOREIGN PATENT DOCUMENTS</b>					
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Bombeli T. et al., "Endothelial Cells Undergoing Apoptosis Become Proadhesive for Nonactivated Platelets", <i>Blood</i> , 93(11):3831-3838 (1999)					
		Martín-Satué M. et al., "Overexpression of $\alpha(1,3)$ -Fucosyltransferase VII is Sufficient for the Acquisition of Lung Colonization Phenotype in Human Lung Adenocarcinoma HAL-24Luc Cells", <i>British Journal of Cancer</i> , 80(8):1169-1174 (1999)					
		Lynch S.M. et al., "Plasma Thiols Inhibit Hemin-Dependent Oxidation of Human Low-Density Lipoprotein", <i>Biochimica et Biophysica Acta</i> , 1485:11-22 (2000)					
		Pedreño J. et al., "Molecular Requirements in the Recognition of Low-Density Lipoproteins (LDL) by Specific Platelet Membrane Receptors", <i>Thrombosis Research</i> , 99:51-60 (2000)					
		Colomé C. et al., "Small Oxidative Changes in Atherogenic LDL Concentrations Irreversibly Regulate Adhesiveness of Human Endothelial Cells: Effect of the Lazaroid U74500A", <i>Atherosclerosis</i> , 149:295-302 (2000)					
		Pedreño J. et al., "Low-Density Lipoprotein (LDL) Binds to a G-Protein Coupled Receptor in Human Platelets, Evidence that the Proaggregatory Effect Induced by LDL is Modulated by Down-Regulation of Binding Sites and Desensitization of its Mediated Signaling", <i>Atherosclerosis</i> , 155:99-112 (2001)					
EXAMINER			DATE CONSIDERED				
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

